Rituximab, sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, leukemias, and some autoimmune disorders.
Rituximab was developed by IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and...